Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY[sub.3-36], and Empagliflozin on Early MASLD in Diet-Induced Obese Rats

(1) Background: Modulators of the Neuropeptide Y (NPY) system are involved in energy metabolism, but the effect of NPY receptor antagonists on metabolic-dysfunction-associated steatotic liver disease (MASLD), a common obesity-related comorbidity, are largely unknown. In this study, we report on the...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Nutrients 2024-03, Vol.16 (6)
Hauptverfasser:	Kloock, Simon, Hae, Herzog, Gloria, Oertel, Marie, Geiger, Niklas, Geier, Andreas, Sequeira, Vasco, Nickel, Alexander, Kohlhaas, Michael, Fassnacht, Ma, Dischinger, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Body weight Dapagliflozin Health aspects International economic relations Liraglutide Liver Liver diseases Scientific equipment and supplies industry Type 2 diabetes Valsartan
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!